CY1109783T1 - Μεθοδοι και συνθεσεις για την αντιμετωπιση της φλεγμονωδους νοσου του πεπτικου - Google Patents

Μεθοδοι και συνθεσεις για την αντιμετωπιση της φλεγμονωδους νοσου του πεπτικου

Info

Publication number
CY1109783T1
CY1109783T1 CY20081100591T CY081100591T CY1109783T1 CY 1109783 T1 CY1109783 T1 CY 1109783T1 CY 20081100591 T CY20081100591 T CY 20081100591T CY 081100591 T CY081100591 T CY 081100591T CY 1109783 T1 CY1109783 T1 CY 1109783T1
Authority
CY
Cyprus
Prior art keywords
treatment
compositions
methods
dental disease
atypical mycobacterial
Prior art date
Application number
CY20081100591T
Other languages
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Thomas Julius Borody
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Thomas Julius Borody filed Critical Thomas Julius Borody
Publication of CY1109783T1 publication Critical patent/CY1109783T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει τη μέθοδο και τη σύνθεση θεραπευτικών μέσων για την αντιμετώπιση της φλεγμονώδους νόσου του πεπτικού. Η εφεύρεση παρέχει επιπλέον συνδυασμούς από αντι-ατυπο-μυκοβακτηριακούς παράγοντες έναντι άτυπων μυκοβακτηριακών στελεχών. Επίσης παρέχει μέθοδο ενεργοποίησης των αντι-ατυπο-μυκοβακτηριακών παραγόντων κατά την αντιμετώπιση της φλεγμονώδους νόσου του πεπτικού ανοσοποιώντας τους ασθενείς με εκχυλίσματα από μη παθογόνα μυκοβακτήρια.
CY20081100591T 1997-04-01 2008-06-05 Μεθοδοι και συνθεσεις για την αντιμετωπιση της φλεγμονωδους νοσου του πεπτικου CY1109783T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
EP98912149A EP0971735B1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CY1109783T1 true CY1109783T1 (el) 2013-09-04

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100591T CY1109783T1 (el) 1997-04-01 2008-06-05 Μεθοδοι και συνθεσεις για την αντιμετωπιση της φλεγμονωδους νοσου του πεπτικου

Country Status (16)

Country Link
US (1) US6277836B1 (el)
EP (1) EP0971735B1 (el)
JP (3) JP2001524951A (el)
AR (1) AR012304A1 (el)
AT (1) ATE389417T1 (el)
CA (1) CA2285923C (el)
CY (1) CY1109783T1 (el)
DE (1) DE69839261T2 (el)
DK (1) DK0971735T3 (el)
ES (1) ES2303351T3 (el)
IL (1) IL132145A (el)
NO (1) NO325947B1 (el)
NZ (1) NZ500696A (el)
PT (1) PT971735E (el)
SI (1) SI0971735T1 (el)
WO (1) WO1998043667A1 (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
WO2000047195A1 (en) * 1999-02-12 2000-08-17 Washington University Stimulating neutrophil function to treat inflammatory bowel disease
AU773218B2 (en) * 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
MXPA02009587A (es) * 2000-03-28 2003-05-14 Biochemie Gmbh Particulas granuladas con sabor enmascarado.
TWI249519B (en) * 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN103948609A (zh) * 2005-08-24 2014-07-30 萨利克斯药品公司 巴柳氮制剂及其生产和应用
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
WO2009047801A1 (en) * 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
DK2247291T3 (en) * 2008-02-08 2019-01-21 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease
CA2721981A1 (en) * 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
NZ598716A (en) 2009-10-26 2014-08-29 Borody Thomas J Novel enteric combination therapy
JP2013525440A (ja) 2010-04-26 2013-06-20 サリックス ファーマシューティカルズ リミテッド 男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
TR201904884T4 (tr) 2012-07-27 2019-05-21 Redhill Biopharma Ltd Koloni̇k boşaltmada kullanima yöneli̇k formülasyonlar ve formülasyonlarin üreti̇m yöntemleri̇
US20150335672A1 (en) 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
MX2018010254A (es) 2016-02-26 2018-12-19 Debiopharm Int Sa Medicamento para el tratamiento de infecciones de pie diabetico.
AU2021298936A1 (en) 2020-06-30 2023-01-19 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
DK0971735T3 (da) 2008-07-07
US6277836B1 (en) 2001-08-21
JP2012126736A (ja) 2012-07-05
CA2285923C (en) 2013-03-12
ATE389417T1 (de) 2008-04-15
EP0971735B1 (en) 2008-03-19
NO994778D0 (no) 1999-09-30
DE69839261T2 (de) 2009-03-26
IL132145A0 (en) 2001-03-19
AR012304A1 (es) 2000-10-18
PT971735E (pt) 2008-06-02
WO1998043667A1 (en) 1998-10-08
JP2008024713A (ja) 2008-02-07
EP0971735A4 (en) 2004-02-25
SI0971735T1 (sl) 2008-08-31
JP2001524951A (ja) 2001-12-04
NZ500696A (en) 2002-05-31
ES2303351T3 (es) 2008-08-01
NO994778L (no) 1999-11-30
NO325947B1 (no) 2008-08-25
CA2285923A1 (en) 1998-10-08
DE69839261D1 (de) 2008-04-30
IL132145A (en) 2005-11-20
EP0971735A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
CY1109783T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της φλεγμονωδους νοσου του πεπτικου
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
CY1105653T1 (el) Στεροειδεις σαπωνινες για τη θεραπεια της νοσου alzheimer
ATE504308T1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
CY1110604T1 (el) Συνδυασμος αναστολεων πρωτεασης που εξαρτωνται απο το κυτοχρωμα ρ450
CY1107087T1 (el) Μιμητικα θρομβοποιητινης
DK1587506T3 (da) Administration af capsaicinoider
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
CY1108740T1 (el) ΕΞΑΝΘΡΩΠΙΣΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΤΑ ΟΠΟΙΑ ΑΝΑΓΝΩΡΙΖΟΥΝ ΤΟ ΠΕΠΤΙΔΙΟ β-ΑΜΥΛΟΕΙΔΟΥΣ
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
BR0107691A (pt) Sapogeninas substituìdas e seu uso
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες